Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

T0014000

Tamoxifen citrate

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Tamoxifen citrate salt, (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C26H29NO · C6H8O7
Numero CAS:
54965-24-1
Peso molecolare:
563.64
Numero MDL:
MFCD00058321
Codice UNSPSC:
41116107
ID PubChem:
329826577
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

tamoxifen

Produttore/marchio commerciale

EDQM

tecniche

HPLC: suitable
gas chromatography (GC): suitable

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3

InChI

1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
FQZYTYWMLGAPFJ-OQKDUQJOSA-N

Informazioni sul gene

human ... ESR1(2099)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Tamoxifen citrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Avvertenze

Danger

Indicazioni di pericolo

H302,H350,H360D,H410

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

(Z)-Endoxifen ≥98% (HPLC)

Sigma-Aldrich

SML2368

(Z)-Endoxifen

(Z) -4-idrossitamoxifene ≥98% Z isomer

Sigma-Aldrich

H7904

(Z) -4-idrossitamoxifene

4-idrossitamoxifene analytical standard, (E) and (Z) isomers (50:50)

Supelco

T176

4-idrossitamoxifene

Estradiol meets USP testing specifications

Sigma-Aldrich

E1024

Estradiol

Doxorubicina European Pharmacopoeia (EP) Reference Standard

D2975000

Doxorubicina

Doxorubicina British Pharmacopoeia (BP) Reference Standard

BP990

Doxorubicina

4-idrossitamoxifene ≥70% Z isomer (remainder primarily E-isomer)

Sigma-Aldrich

H6278

4-idrossitamoxifene

Trichostatin A ≥98% (HPLC), from Streptomyces sp.

Sigma-Aldrich

T8552

Trichostatin A

cis-Diammineplatinum(II) dichloride crystalline

Sigma-Aldrich

P4394

cis-Diammineplatinum(II) dichloride

Kevin S Hughes et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2382-2387 (2013-05-22)
To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had
P Fox et al.
British journal of cancer, 109(1), 147-153 (2013-06-20)
The host inflammatory response has a vital role in carcinogenesis and tumour progression. We examined the prognostic value of inflammatory markers (albumin, white-cell count and its components, and platelets) in pre-treated patients with advanced renal cell carcinoma (RCC). Using data
K I Pritchard
Journal of internal medicine, 274(2), 144-152 (2013-07-13)
Hormonal therapy for breast cancer is the first targeted therapy used in any type of cancer. It was used successfully without a known target for more than 50 years before Jensen described the oestrogen receptor (ER) in the 1960s. Subsequently, it
Esther Castellano et al.
Cancer cell, 24(5), 617-630 (2013-11-16)
RAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS binding domain of the p110α subunit of PI3-kinse are resistant to the development of RAS-driven tumors. However, it is unknown whether interaction of RAS with PI3-kinase is
Matthew A Firth et al.
The Journal of experimental medicine, 210(13), 2981-2990 (2013-11-28)
Development of the natural killer (NK) cell lineage is dependent on the transcription factor Nfil3 (or E4BP4), which is thought to act downstream of IL-15 signaling. Nfil3-deficient mice lack NK cells, whereas other lymphocyte lineages (B, T, and NKT cells)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.